ANKYLOSING SPONDYLITIS

ASLeap is a study of adults who have been diagnosed with moderate to severe ankylosing spondylitis (AS). About 270 patients will join this study at approximately 82 medical centers in the United States. The ASLeap study will help researchers determine the safety and benefit of taking secukinumab at 300 mg, compared to the currently used dose of 150 mg, in patients with active ankylosing spondylitis. The study will also look at how secukinumab affects your daily activity (i.e., movement) and quality of sleep.